中药注射剂治疗心源性休克的疗效比较:系统评价与贝叶斯网络Meta分析
该研究纳入43项RCT共2707例心源性休克患者,比较6种中药注射剂联合西医与单用西医的疗效。贝叶斯网络Meta分析显示,参麦注射液和参附注射液在降低院内死亡率方面优于单用西医;参麦注射液联合西医在院内死亡率、心脏指数和每小时尿量方面排名第一。
要点
- 参麦注射液联合西医在降低院内死亡率、改善心脏指数和每小时尿量方面排名第一。
- 参附注射液联合西医在提高临床有效率方面排名第一。
- 中药注射剂联合西医整体优于单用西医,但安全性报告仅14项研究(31.8%)。
核心结论
- 中药注射剂联合西医治疗心源性休克较单用西医具有显著优势。
- 基于院内死亡率及其他结局,参麦注射液在涉及的注射剂中表现最优。
研究设计与样本
- 系统评价与贝叶斯网络Meta分析,检索8个数据库至2023年9月30日。
- 纳入43项随机对照试验,共2707例参与者。
- 评估6种中药注射剂:参附、生脉、参麦、丹参、黄芪、心脉隆注射液。
主要发现
- 参麦注射液(MD=-1.05,95%CI:-2.10,-0.09)和参附注射液(MD=-0.81,95%CI:-1.40,-0.25)在降低院内死亡率方面优于单用西医。
- SUCRA值显示参麦注射液联合西医在院内死亡率、心脏指数和每小时尿量方面排名第一,在改善左心室射血分数和平均动脉压方面排名第二。
- 参附注射液联合西医对提高临床有效率影响最大;生脉注射液联合西医在平均动脉压方面排名第一。
- 安全性方面,仅14项研究(31.8%)报告了药物不良反应,涉及参附、参麦、生脉、黄芪和心脉隆五种注射剂。
临床怎么用
- 对于心源性休克患者,可考虑在常规西医治疗基础上联合中药注射剂以改善预后。
- 参麦注射液联合西医可能优先用于降低院内死亡率和改善心脏指数及尿量。
- 参附注射液联合西医可能优先用于提高临床有效率。
局限性
- 仅31.8%的研究报告了药物不良反应,安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Cardiogenic shock (CS) is the primary cause of death in patients suffering acute myocardial infarction. As an emerging and efficacious therapeutic approach, Chinese herbal injections (CHIs) are gaining significant popularity in China. However, the optimal CHIs for treating CS remain uncertain. Method: We searched eight databases from inception to 30 September 2023. Subsequently, we conducted the Bayesian network meta-analysis (NMA). Interventions were ranked based on the surface under the cumulative ranking curve (SUCRA) probability values. To compare the effects of CHIs on two distinct outcomes, a clustering analysis was performed. Furthermore, the quality of the studies was assessed. Results: For the study, we included 43 RCTs, encompassing 2,707 participants. The study evaluated six herbal injections, namely, Shenfu injection (SF), Shengmai injection (SM), Shenmai injection (Sm), Danshen injection (DS), Huangqi injection (HQ), and Xinmailong injection (XML). The analysis findings suggested that Sm (MD = -1.05, 95% CI: -2.10, -0.09) and SF (MD = -0.81, 95% CI: -1.40, -0.25) showed better efficacy compared to Western medicine (WM) alone in reducing in-hospital mortality. The SUCRA values revealed that Sm + WM ranked first in terms of in-hospital mortality, cardiac index (CI), and hourly urine output but second in improving left ventricular ejection fraction (LVEF) and mean arterial pressure (MAP). SF + WM, however, had the greatest impact on raising the clinical effective rate. In MAP, SM + WM came out on top. Moreover, in terms of safety, only 14 studies (31.8%), including five types of CHIs: SF, Sm, SM, HQ, and XML, observed adverse drug reactions. Conclusion: To summarize, this analysis discovered that, in terms of patients suffering from CS, CHIs + WM yielded significantly greater advantages than WM alone. Based on in-hospital mortality and the remaining outcomes, Sm performed excellently among all the involved CHIs. Systematic Review Registration: https:// www.Crd.york.ac.uk/prospero/, identifier: CRD42022347053.
引用
- Yue L, Xiao L, Zhang X, et al. Comparative efficacy of Chinese herbal injections in patients with cardiogenic shock (CS): a systematic review and Bayesian network meta-analysis of randomized controlled trials. Front Pharmacol. 2024. PMID: 38476325. doi:10.3389/fphar.2024.1348360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。